United States (US) CAR T-Cell Immunotherapy Market (2025-2031) | Companies, Trends, Value, Competitive Landscape, Industry, Segmentation, Outlook, Forecast, Share, Size & Revenue, Growth, Analysis

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) CAR T-Cell Immunotherapy Market - Industry Life Cycle

3.4 United States (US) CAR T-Cell Immunotherapy Market - Porter's Five Forces

3.5 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume Share, By Product, 2021 & 2031F

3.6 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume Share, By Application, 2021 & 2031F

3.7 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume Share, By Target Antigen, 2021 & 2031F

3.8 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume Share, By End Users, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of cancer in the US

4.2.2 Growing investments in research and development for immunotherapy

4.2.3 Favorable regulatory environment supporting the adoption of CAR T-cell therapy

4.3 Market Restraints

4.3.1 High treatment costs associated with CAR T-cell immunotherapy

4.3.2 Limited accessibility and affordability for a broader patient population

4.3.3 Potential side effects and safety concerns related to CAR T-cell therapy

6.1 United States (US) CAR T-Cell Immunotherapy Market, By Product

6.1.1 Overview and Analysis

6.1.2 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, By Product, 2021- 2031F

6.1.3 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, By Allogeneic CAR T-Cells, 2021- 2031F

6.1.4 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, By Autologous CAR T-Cells, 2021- 2031F

6.2 United States (US) CAR T-Cell Immunotherapy Market, By Application

6.2.1 Overview and Analysis

6.2.2 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, By Diffuse Large B-Cell Lymphoma, 2021- 2031F

6.2.3 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, By Acute Lymphoblastic Leukemia, 2021- 2031F

6.3 United States (US) CAR T-Cell Immunotherapy Market, By Target Antigen

6.3.1 Overview and Analysis

6.3.2 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, By CD19, 2021- 2031F

6.3.3 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, By CD22, 2021- 2031F

6.4 United States (US) CAR T-Cell Immunotherapy Market, By End Users

6.4.1 Overview and Analysis

6.4.2 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, By Hospital, 2021- 2031F

6.4.3 United States (US) CAR T-Cell Immunotherapy Market Revenues & Volume, By Diagnostic Center, 2021- 2031F

7.1 United States (US) CAR T-Cell Immunotherapy Market Export to Major Countries

7.2 United States (US) CAR T-Cell Immunotherapy Market Imports from Major Countries

8.1 Average waiting time for CAR T-cell therapy treatment

8.2 Number of clinical trials for CAR T-cell therapies in the US

8.3 Patient satisfaction rate with CAR T-cell immunotherapy treatments

9.1 United States (US) CAR T-Cell Immunotherapy Market Opportunity Assessment, By Product, 2021 & 2031F

9.2 United States (US) CAR T-Cell Immunotherapy Market Opportunity Assessment, By Application, 2021 & 2031F

9.3 United States (US) CAR T-Cell Immunotherapy Market Opportunity Assessment, By Target Antigen, 2021 & 2031F

9.4 United States (US) CAR T-Cell Immunotherapy Market Opportunity Assessment, By End Users, 2021 & 2031F

10.1 United States (US) CAR T-Cell Immunotherapy Market Revenue Share, By Companies, 2024

10.2 United States (US) CAR T-Cell Immunotherapy Market Competitive Benchmarking, By Operating and Technical Parameters